Biohaven's BHV-1510 Shows 100% Response Rate in Endometrial Cancer Trial
Biohaven's (BHVN) BHV-1510 cancer drug shows impressive response rates in lung, endometrial, and bladder cancers with fewer side effects than similar treatments.
Biohaven's (BHVN) BHV-1510 cancer drug shows impressive response rates in lung, endometrial, and bladder cancers with fewer side effects than similar treatments.
UBS cuts Biohaven to Neutral from Buy, lowering the price target to $11 due to multiple R&D and regulatory setbacks and rising competition in its Kv7 program.
FDA denies Biohaven's troriluzole approval for spinocerebellar ataxia citing real-world evidence concerns. Company cuts R&D spending 60% and refocuses on three key late-stage programs.
UniQure's stock plummeted after the FDA unexpectedly decided that the current clinical trial data for its promising Huntington's disease therapy, AMT-130, is not adequate for immediate marketing application (BLA).